Activation_NN
of_IN
nuclear_JJ
factor-kappaB_NN
by_IN
lipopolysaccharide_NN
in_IN
mononuclear_JJ
leukocytes_NNS
is_VBZ
prevented_VBN
by_IN
inhibitors_NNS
of_IN
cytosolic_JJ
phospholipase_NN
A2_NN
._.

In_IN
monocytes_NNS
,_,
lipopolysaccharide_NN
induces_VBZ
synthesis_NN
and_CC
activity_NN
of_IN
the_DT
85-kDa_JJ
cytosolic_JJ
phospholipase_NN
A2_NN
._.

This_DT
enzyme_NN
releases_VBZ
arachidonic_JJ
acid_NN
and_CC
lyso-phospholipids_NNS
from_IN
membranes_NNS
which_WDT
are_VBP
metabolized_VBN
to_TO
eicosanoids_NNS
and_CC
platelet-activating-factor_NN
._.

These_DT
lipid_NN
mediators_NNS
increase_VBP
activity_NN
of_IN
transcription_NN
factors_NNS
and_CC
expression_NN
of_IN
cytokine_NN
genes_NNS
indicating_VBG
a_DT
function_NN
for_IN
cytosolic_JJ
phospholipase_NN
A2_NN
in_IN
signal_NN
transduction_NN
and_CC
inflammation_NN
._.

We_PRP
have_VBP
shown_VBN
previously_RB
that_IN
trifluoromethylketone_NN
inhibitors_NNS
of_IN
cytosolic_JJ
phospholipase_NN
A2_NN
suppressed_VBD
interleukin-1beta_NN
protein_NN
and_CC
steady-state_JJ
mRNA_NN
levels_NNS
in_IN
human_JJ
lipopolysaccharide-stimulated_JJ
peripheral_JJ
blood_NN
mononuclear_JJ
leukocytes_NNS
._.

In_IN
this_DT
study_NN
,_,
the_DT
subcellular_JJ
mechanisms_NNS
were_VBD
analyzed_VBN
by_IN
which_WDT
trifluoromethylketones_NNS
interfere_VBP
with_IN
gene_NN
expression_NN
._.

We_PRP
found_VBD
that_IN
they_PRP
reduced_VBD
the_DT
initial_JJ
interleukin-1beta_NN
mRNA_NN
transcription_NN
rate_NN
through_IN
prevention_NN
of_IN
degradation_NN
of_IN
inhibitor-kappaB_NN
alpha_NN
._.

Consequently_RB
,_,
cytosolic_JJ
activation_NN
,_,
nuclear_JJ
translocation_NN
and_CC
DNA-binding_NN
of_IN
nuclear_JJ
factor-kappaB_NN
were_VBD
decreased_VBN
._.

Trifluoromethylketones_NNS
ameliorate_VBP
chronic_JJ
inflammation_NN
in_FW
vivo_FW
._.

Thus_RB
,_,
this_DT
therapeutic_JJ
potency_NN
may_MD
reside_VB
in_IN
retention_NN
of_IN
inactive_JJ
nuclear_JJ
factor-kappaB_NN
in_IN
the_DT
cytosol_NN
thereby_RB
abrogating_VBG
interleukin-1beta_NN
gene_NN
transcription_NN
._.

